Cali McEntee

Postdoctoral Research Fellow @umich_NeuroNet University of Michigan

[Keita Masui @keita_masui]

老化は種を越えて共通の「言葉」で書かれているのかもしれない。Natureに掲載された報告は、マウスからヒトまで4種・25組織・1万超の遺伝子発現を統合し、哺乳類に普遍的な老化・死亡のシグネチャを同定した。しかも老化を、炎症・ミトコンドリア・細胞外マトリックスなど28のモジュールに分解した。

意義は、介入の設計図になる点だ。慢性疾患は炎症モジュールを、カロリー制限は代謝モジュールを動かす——どの介入が老化のどの側面に効くかが見える。老化を一つの数字ではなく「制御可能な回路の集合」として捉える。抗老化創薬が、狙いを定めて設計できる段階に近づいている。

出典: Nature（2026）
https://t.co/uxe8XVLkPb

[Neuron @NeuroCellPress]

Online now: Senescent cell heterogeneity in brain aging and neurodegenerative disease https://t.co/JZu8dphayf

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

Biological aging clocks in health and disease

@wysscoray @NatureMedicine

🔗https://t.co/CEyhZEZ7Bw

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

Exercise mimetics: molecular mechanisms, biological and therapeutic effects

https://t.co/YAs49T4uqF

[nature @Nature]

What can actually be done to lower dementia risk?

https://t.co/n1qjxyMVH4

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

Are GLP-1 receptor agonists gerotherapeutics or just treatments for obesity?

@JamesPeyer

https://t.co/8RhtV7shf3

[Cell Metabolism @Cell_Metabolism]

How to train your rodent: Recommendations for the preclinical study of exercise-induced benefits in metabolic research https://t.co/DAcg3ik0mi

[Eva Feldman, MD, PhD @EvaFeldmanMDPhD]

In a new review in @ANAneurology’s Annals of Neurology, we propose a new term, “stocking-glove-hat,” to highlight the risk of cognitive problems and potentially dementia in people with diabetes who have peripheral neuropathy.

@TheSciGency

https://t.co/1BB73JhaMm

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

Ozempic just took its biggest swing at Alzheimer’s.

…and missed.

That sounds like bad news—until you realize what we finally got:

A clean, Phase 3 answer to one of the most hyped “repurposing” bets in medicine.

Because for a year, the storyline was everywhere:

GLP-1 drugs help the heart.
Help the kidneys.
Help weight.
Help inflammation.
So people started asking the most tempting question of all:
Could they help the brain, too?
The setup was blockbuster-level

Novo Nordisk ran two huge, randomized, placebo-controlled Phase 3 trials—EVOKE and EVOKE+:

→ 3,808 people (ages 55–85)
→ Early symptomatic Alzheimer’s (MCI or mild dementia) with confirmed amyloid positivity
→ Once-daily oral semaglutide 14 mg (Rybelsus) vs placebo
→ 104 weeks of treatment, with a planned 52-week extension

This wasn’t “signals.”
This wasn’t “maybe.”
This was the class getting tested under stadium lights.

The headline outcome

Semaglutide did not slow Alzheimer’s progression.
On the primary endpoint (CDR-Sum of Boxes):
→ EVOKE: estimated difference –0.06 points vs placebo (P = .7727)
→ EVOKE+: estimated difference 0.15 points (P = .4604)
Secondary outcomes didn’t rescue it either:

→ No meaningful functional slowing on ADCS-ADL-MCI
→ No clear benefit on major cognition scales
→ No delay in progression to dementia from MCI (pooled HR 0.96)
And Novo dropped the planned 1-year extension based on the overall results.
Here’s the part most headlines miss

Biology moved. People didn’t.

In a CSF biomarker substudy (199 participants):

→ ~10% “nominally significant” reductions in several AD-relevant markers (including p-tau measures)
→ plus shifts in markers tied to inflammation and synaptic injury

Blood markers also showed something:
→ hs-CRP fell (systemic inflammation signal)
→ but some exploratory markers like NfL and GFAP increased (small but statistically significant in places), complicating the picture

Translation:

Semaglutide wasn’t “doing nothing.”
It just wasn’t doing enough, in the right place, at the right time to change real-world decline.
So why is this exciting?
Because it resolves a major confusion that was fueling false hope:

Prevention signals ≠ treatment success.

A JAMA Neurology–published study in people with type 2 diabetes supported continued investigation by showing lower Alzheimer’s risk in those on GLP-1 receptor agonists (and also SGLT2 inhibitors) compared with other glucose-lowering drugs—and no clear difference between GLP-1RAs and SGLT2is overall.

One line that captures the “why keep looking?” logic:

“patients with type 2 diabetes receiving GLP-1 receptor agonists… had a significantly lower risk of developing AD”

That’s the paradox:
→ In diabetes populations, GLP-1s look protective in real-world data
→ In symptomatic Alzheimer’s, semaglutide doesn’t slow decline in Phase 3

Those two things can both be true if the real opportunity is upstream.

What the trials actually taught us (the “new map”)
Lowering systemic inflammation/metabolic stress isn’t a solo fix once symptoms start.

Timing may be everything. The field is now openly talking about dose, population, and even designing drugs that enter the brain more effectively.

Alzheimer’s is drifting toward an oncology-style era: combinations + precision subgroups.
The follow-up everyone should watch

The story isn’t “done.”

What’s next is the deep dive:

→ subgroup analyses (who, if anyone, benefited?)
→ mechanistic readouts (which pathways moved, which didn’t?)
→ and how to pair metabolic drugs with other disease-modifying strategies

And full EVOKE/EVOKE+ results are expected to be presented at AD/PD in March 2026.

The most credible “exciting ending” here

The Ozempic-Alzheimer’s dream didn’t die.

It evolved.

From:
→ “One blockbuster drug fixes Alzheimer’s.”

To something more realistic—and potentially more powerful:

→ Treat earlier.
→ Target multiple pathways at once.
→ Use blood biomarkers to match the right patient to the right combo.

Alzheimer’s has been the graveyard of single-shot miracles.

EVOKE didn’t give us a miracle.

It gave us something rarer:

A massive, expensive, definitive result that tells researchers exactly where not to stand… so the next trials can finally aim where it might actually work.

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

Obesity and biological aging across the life course: A geroscience framework for metabolic health

https://t.co/gRRL1O9MnY

[Eva Feldman, MD, PhD @EvaFeldmanMDPhD]

What an incredible talk @CaliMcEntee gave today at the 22nd Annual Neurobiology of Disease Symposium. We are so proud!

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

Increased genetic protection against Alzheimer’s disease in centenarians

https://t.co/h9dWWPk51J @GeroScienceAGE

[Aging Science News @AgingBiology]

Exceptional Longevity Modifying Allele APOE2 Promotes DNA Signaling Pathways Resisting Cellular Senescence in Human Neurons
https://t.co/33JE5m6eIw

[Neurology Journal @GreenJournal]

New research suggests that higher cognitive and brain reserve may help buffer the cognitive effects of Alzheimer disease pathology. Building these reserves could play a role in strengthening resilience against emerging #AlzheimerDisease pathology: https://t.co/MSJvaDs3Wg

[Neurology Journal @GreenJournal]

Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited #AlzheimerDisease https://t.co/BGoQ4c4Hg3

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

Hallmarks of healthy cognitive aging: inter-individual differences in aging trajectories

https://t.co/YszLD7KiXk

[Aging Science News @AgingBiology]

Transcriptional profiles of immature neurons in aged human hippocampus track Alzheimer’s pathology and cognitive resilience
https://t.co/ryXsBImfG3

[Nature Aging @NatureAging]

Online now!✨Lin, Shao, Shi et al identify a mechanism by which swimming exercise attenuates cognitive decline in Alzheimer's disease mice. Skeletal muscle-derived vesicles act as myokines, regulating lipid metabolism and plaque clearance in microglia https://t.co/fsB54NMZfB

[Danny Arends @DannyArends]

Our paper in @Nature today 🥳 We tracked 6,438 mice from puberty to death and mapped the genetics of *when* you die, not just whether a gene associates with lifespan.

https://t.co/EoeexqJoHk

59 loci. Two decades of data. Thread 👇

#Longevity #Aging #Genetics #Healthspan

[American Heart Association - Michigan @MichiganAHA]

The @AANmember and the @american_heart have awarded one of the two 2026 Ralph L. Sacco Scholarships for Brain Health to Cali McEntee, Ph.D., of Ann Arbor, Michigan. She will receive a $150,000 two-year scholarship to support continuing scientific research in brain health.